Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kardia Band

- PMLiVE

FDA approves Abeona’s epidermolysis bullosa gene therapy Zevaskyn

The sheet-based treatment is expected to be available from the third quarter of this year

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq granted FDA approval to treat giant cell arteritis

The drug could allow patients to taper off steroids and achieve sustained remission

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

FDA approves pre-filled syringe version of argenx’s immune disorder drug Vyvgart

The authorisation will give patients the flexibility to decide when and where they receive treatment

- PMLiVE

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

Bayer symbol

Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer

Around half of patients who undergo bladder removal surgery experience disease recurrence

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours

Approximately 380,000 people in the US were affected by NETs in 2024

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links